secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apogee Therapeutics, Inc. (APGE)
CIK:        0001974640
Form:       8-K
Filed at:   2025-10-10T23:59:59+00:00
Accession:  0001104659-25-098487
Event type: other_material
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apogee (APGE) raises $323M, updates APG777 atopic dermatitis and asthma trials
------------------------------------------------------------------------------

- Offering of 6.95M shares at $41 plus pre-funded warrants and full underwriter option exercise, net proceeds ~$323.3M.
- APG777 APEX atopic dermatitis trial enrollment increased to 320 patients; Part B enrollment expected by year-end 2025.
- Topline maintenance data from APEX Part A expected Q1 2026; 16-week induction data from Part B in Q2 2026.
- Phase 1b asthma topline data for APG777 expected in Q1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1974640/000110465925098487/0001104659-25-098487-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1974640/000110465925098487/tm2528385d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-098487

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer